Bristol-myers Squibb Stock News

Bristol-Myers Squibb Company with ticker code (BMY) have now 20 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 94 and 58 with the average target price sitting at 72.5. Now with the previous closing price of 67.1 this is indicating there is a potential upside of 8.0%. There is a 50 day moving average of 64.35 and the 200 moving average now moves to 63.44. The company has a market cap of $152,711m. Find out more information at: https://www.bms.com [stock_market_widget type="chart" template="basic" color="green" assets=BMY" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $165,001m based on the market concensus. Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company''s products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.

The final trades of the week. With CNBC's Melissa Lee and the Fast Money traders, Dan Nathan, Jeff Mills, Guy Adami and Adam Parker.

Iovance Biotherapeutics' (IOVA) fourth-quarter loss is wider than expected. The company is on track to file regulatory submission for lifileucel in melanoma by first-half 2022.

Bristol Myers Squibb & Co (NYSE: BMY ) has received positive CHMP opinion for Opdivo (nivolumab) plus chemotherapy for first-line treatment of unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has

Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN ) has entered into a global license agreement with Bristol Myers Squibb & Co (NYSE: BMY ) to develop and commercialize taldefgrobep alfa. Taldefgrobep, a Phase 3-ready anti-myostatin adnectin, is the third development asset licensed to Biohaven from Bristol Myers Squibb. The Company will initiate the taldefgrobep Phase 3 trial for Spinal Muscular Atrophy (SMA) in 2022. Bristol Myers Squibb will be eligible for regulatory approval milestone … Full story available on Benzinga.com

Bristol Myers Squibb (BMY) said a committee of the European Medicines Agency ((EMA)) recommended approval of Opdivo (nivolumab) for the adjuvant treatment of adults with…

Coinciding with the company’s Q4 2021 results, neurology-focused biotech, Biohaven Pharmaceutical (BHVN) announced a licensing deal with Bristol Myers Squibb (BMY) and an agreement…

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--BMS Receives Positive CHMP Opinion for Opdivo plus Chemotherapy for First-Line Treatment of Patients with Unresectable, Advanced, Recurrent….

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--BMS Receives Positive CHMP Opinion Recommending Approval for Opdivo plus Yervoy for First-line Treatment of Patients with….

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--BMS Receives Positive CHMP Opinion Recommending Approval for Opdivo as Adjuvant Treatment for Patients with Radically Resected….

We think that Bristol Myers Squibb stock currently is a better pick compared to its industry peer Johnson & Johnson stock, given its better growth prospects and comparatively lower valuation of 3.2x t

Clovis (CLVS) reports narrower-than-expected loss for fourth-quarter 2021. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.

Bristol-Myers Squibb saw an improvement in its IBD SmartSelect Composite Rating Friday, from 94 to 96.

Bristol-Myers Squibb Company (NYSE:BMY) makes and sells biopharma products. Hedge funds are exceedingly bullish on the stock.

Exelixis (EXEL) beats on both earnings and revenues in the fourth quarter. Both figures increase on a year-over-year basis.